Dihydroartemisinin Is Cytotoxic to Papillomavirus-Expressing Epithelial Cells In vitro and In vivo

Gary L. Disbrow, Astrid C. Baege, Katie A. Kierpiec, Hang Yuan, Clare A. Thibodeaux, Dan Hartmann, and Richard Schlegel

1Department of Pathology, Georgetown University Medical Center and 2Department of Environmental and Infectious Disease Sciences, Armed Forces Institute of Pathology, Washington, District of Columbia

Abstract

Nearly all cervical cancers are etiologically attributable to human papillomavirus (HPV) infection and pharmaceutical treatments targeting HPV-infected cells would be of great medical benefit. Because many neoplastic cells (including cervical cancer cells) overexpress the transferrin receptor to increase their iron uptake, we hypothesized that iron-dependent, antimalarial drugs such as artemisinin might prove useful in treating HPV-infected or transformed cells. We tested three different artemisinin compounds and found that dihydroartemisinin (DHA) and artemesunate displayed strong cytotoxic effects on HPV-immortalized and transformed cervical cells in vitro with little effect on normal cervical epithelial cells. DHA-induced cell death involved activation of the mitochondrial caspase pathway with resultant apoptosis. Apoptosis was p53 independent and was not the consequence of drug-induced reductions in viral oncogene expression. Due to its selective cytotoxicity, hydrophobicity, and known ability to penetrate epithelial surfaces, we postulated that DHA might be useful for the topical treatment of mucosal papillomavirus lesions. To test this hypothesis, we applied DHA to the oral mucosa of dogs that had been challenged with the canine oral papillomavirus. Although applied only intermittently, DHA strongly inhibited viral-induced tumor formation. Interestingly, the DHA-treated, tumor-negative dogs developed antibodies against the viral L1 capsid protein, suggesting that DHA had inhibited tumor growth but not early rounds of papillomavirus replication. These findings indicate that DHA and other artemisinin derivatives may be useful for the topical treatment of epithelial papillomavirus lesions, including those that have progressed to the neoplastic stage. (Cancer Res 2005; 65(23): 10854-61)

Introduction

Cervical cancer is a global health problem, representing the primary cause of cancer-related female deaths in developing countries (1). Infection with high-risk human papillomaviruses (HPV) has been established as a precursor of cervical cancer and ~99% of cervical cancers contain a “high-risk” papillomavirus genome, with 50% to 60% of these cases due to a single HPV genotype, HPV-16 (2). Given the significant economic burden to health care systems for detecting and treating HPV-induced lesions and the need for inexpensive therapeutic approaches to treat such lesions, we initiated a study to investigate the efficacy of artemisinin compounds to kill HPV-16 E6 and E7 immortalized ectocervical cells and several established cervical cancer cell lines.

Artemisinin, the active principle of the Chinese medicinal herb Artemisia annua (3, 4), and its derivatives are very effective blood schistosidal antimalarials with fewer adverse side effects than any other antimalarial drug. Recommended by the WHO, the drug has been used to treat more than 2 million people, mainly in Africa and Asia (5). Artemisinin contains an endoperoxide bridge that reacts with ferrous iron to generate free radicals, leading to macromolecular damage and cell death (4–6). Recently, certain artemisinin derivatives were shown to inhibit the growth of a limited set of human cancer cell lines (7). In a subsequent study, the cervical cancer cell line HeLa was also shown to be sensitive to DHA although a mechanism for cell death was not elucidated (8). We speculated that both cervical cancer and immortalized cell lines, which are sensitized to apoptotic cell death by the expression of the E6 and E7 oncogenes (9–13) and overexpress the transferrin receptor (14–16), might be killed by these antimalarial compounds.

In this study, we investigated the specificity of artemisinin and two of its derivatives on a panel of cell lines that represent various stages of cancer progression. These cells included primary, HPV-immortalized, and tumorigenic cervical cells. We show that the HPV-immortalized and tumorigenic cervical cells are sensitive to DHA and artemesunate and that these cells express higher levels of transferrin receptor and intracellular iron (compared with normal ectocervical cells). Indeed, iron is required for the drug-induced formation of reactive oxygen species (ROS), the activation of caspases, and consequent apoptosis. Most importantly, we show that DHA can inhibit mucosal tumors induced in animals by papillomavirus, suggesting that this class of drugs may have clinical applications additional to the well-studied antimalarial activities. For example, the topical application of artemisinin derivatives to early cervical dysplasia could greatly simplify the treatment of such papillomavirus-related lesions, including those in immunocompromised patients.

Materials and Methods

Cells and cell culture. Control ectocervical cells, transduced with empty retrovirus, and immortalized ectocervical cells representing preimmortalization (five passages after transduction with the E6 and E7 oncogenes) and postimmortalization (50 passages after transduction) have previously been described (17, 18). Ectocervical cells expressing E6 or E7 independently were transduced with retroviruses encoding each gene and selected as previously described (17). All ectocervical cells were maintained in modified Keratinocyte Growth Medium (Invitrogen, Carlsbad, CA) as described (17, 18). HeLa, SiHa, and Caski cells were obtained from the American Type Culture Institute.

Note: G.L. Disbrow, A.C. Baege, and K.A. Kierpiec contributed equally to this work. Requests for reprints: Richard Schlegel, Department of Pathology, Georgetown University Medical Center, 9900 Reservoir Road Northwest, Washington, DC 20057. Phone: 202-687-7733; Fax: 202-687-9934; E-mail: schleg@georgetown.edu.

©2005 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-05-1216
Collection (Manassas, VA) and maintained in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Quality Biological, Inc., Gaithersburg, MD) and penicillin/streptomycin (Invitrogen).

Neutral assay for cell survival. Cells, 5 × 10^4, were plated in duplicate in 12-well plates (Falcon). Twenty-four hours after plating, cells were treated for 3 days with the indicated concentrations of artemisinin (Sigma Chemical, St. Louis, MO), dihydroartemisinin [DHA; Calbiochem, San Diego, CA (discontinued)] or a gift from Holley Pharmaceuticals, Inc., Fullerton, CA, or artesunate (gift from Holley Pharmaceuticals). All three compounds were dissolved in DMSO (Sigma Chemical). The wells were washed with PBS and appropriate medium containing neutral red (Invitrogen) was added. The cells were incubated at 37°C for 2 hours in 5% CO2. The cells were washed thrice with PBS and then lysed in a solution of glacial acetic acid (1%)/ethanol (100%) (50:50; both from Baker Scientific, Phillipsburg, NJ) with rocking for 2 to 5 minutes at room temperature. Lysates were collected and 100 µL were analyzed in an Opsys MR plate reader (Dynex, Chantilly, VA) at a wavelength of 540 nm. The resulting cell viability number is the average of two wells and the experiment was repeated thrice with identical results. The assay was standardized and shown to be linear over the values obtained in these experiments (data not shown).

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for cell viability. HeLa cells were plated in triplicate in 96-well microtiter plates (Falcon) at 2 × 10^3 cells per well. Twenty-four hours later, the cells were treated with either vehicle (H2O) or desferrioxamine dissolved in H2O at the concentrations indicated for 6 hours. After the pretreatment, the media was replaced with media containing various concentrations of DHA with or without desferrioxamine added to maintain the concentration of desferrioxamine in the wells. After 24 hours of DHA treatment, cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Chemicon International, Temecula, CA) as per protocol of the manufacturer. The resulting cell viability number is the average of three wells and the experiment was repeated thrice with identical results.

Annexin V and propidium iodide staining. Control ectocervical cells (HCX) were plated at 1 × 10^5 and HeLa cells at 2 × 10^5 both in 60-mm tissue culture dishes (Falcon). Twenty-four hours later, the cells were treated with various concentrations of DHA for 3 days. At the end of 3 days, the cells were trypsinized and stained with the Annexin V propidium iodide kit (BD PharMingen, San Diego, CA) as per protocol of the manufacturer. Cells were subjected to fluorescence-activated cell sorting (FACS) analysis. The data presented are representative of results from at least two independent experiments.

Western blot. Cells, 1 × 10^6, were plated in 100-mm tissue culture dishes (Falcon). After 24 hours, the cells were pretreated with desferrioxamine or left untreated for 6 hours, then treated overnight with various concentrations of DHA or DHA + desferrioxamine. The cells were lysed in 2X Laemmli’s buffer and boiled for 10 minutes. Protein concentrations were determined using a detergent-compatible protein assay kit from Bio-Rad (Hercules, CA). β-Mercaptoethanol (Sigma Chemical) was added to 10% of the final volume and equal amounts of protein were loaded on 4% to 20% gradient polyacrylamide gels (Invitrogen) and separated by electrophoresis. Proteins were then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA) and probed with antibodies against total caspase-9, caspase-3, caspase-7, and poly(ADP-ribose) polymerase or cleaved caspase-9, caspase-3, caspase-7, and poly(ADP-ribose) polymerase obtained from the apoptosis kit (Cell Signal, Beverly, MA) at dilutions of 1:2000. To determine activation of other caspases, antibodies against caspase-12 (BD PharMingen) at a concentration of 1:2000, caspase-8 (CN Biosciences, San Diego, CA) at 1:100, and caspase-10 ( Trevigen, Gaithersburg, MD) at 1:1000 were used. Additionally, p53 was detected using an anti-p53 antibody (Cell Signal) at 1:1000 and E7 was detected using an anti-E7 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:500. To analyze for the level of transferrin receptor, 2 × 10^5 cells were plated (all cell lines) and lysed 24 hours later in SDS lysis buffer as previously described (18). Samples were separated on a 10% Tris-glycine gel (Invitrogen) and the membrane was probed with transferrin receptor antibody (BD Pharmingen) at 1:100. To ensure equal loading, all membranes were reprobed using an anti-β-actin antibody (Sigma Chemical) at 1:10,000.

Measurement of reactive oxygen species. Production of ROS was determined using 6-carboxy-2,7'-dihydrofluorescein-diacetate (Molecular Probes, Eugene, OR) and FACS analysis as described (19, 20). HeLa cells, 1 × 10^5, were seeded into 100-mm plates. Twenty-four hours later, the cells were incubated for 1 hour in 6-carboxy-2,7'-dihydrofluorescein-diacetate at a concentration of 5 µmol/L in DMEM and simultaneously treated with 25 or 100 µmol/L DHA. Some cells also were pretreated with 150 µmol/L.

Figure 1. Effects of artemisinin, artesunate, and dihydroartemisinin on normal, immortalized, and tumorigenic cervical cells. A, HeLa cells were treated with various concentrations of artemisinin, artesunate, or DHA for 3 days. Cell survival was measured using the neutral red assay. The IC50 for artesunate and DHA was determined to be 5 and 7.5 µmol/L, respectively. B, normal cervical epithelial cells (HCX) were treated as in (A). At the end of the 3-day treatment, cell survival was measured using the neutral red assay. Normal cervical cells were very resistant to all three compounds tested. C, ectocervical epithelial cells transduced with empty retrovirus (HCX), ectocervical cells transduced with HPV-16 E6 or E7 independently, cervical cells transduced with HPV-16 E6/E7, preimmortalization (early p5) and postimmortalization (late p50), and cervical cancer cells (HeLa, SiHa, and Caski) were treated with DHA for 3 days. At the end of the treatment, cell viability was measured with a neutral red assay. All tumorigenic and HPV-immortalized cell lines were sensitive to DHA with HeLa showing the greatest sensitivity. After treatment with 50 µmol/L DHA for 3 days, 98% of HeLa cells were killed. In contrast, normal cervical cells were minimally affected. Points, mean of two wells from experiments carried out three separate times.
DHA and desferrioxamine at the original concentration was then added. After 24 hours of DHA treatment, cell viability was measured using MTT assay. Desferrioxamine later, the cells were either treated with desferrioxamine at the concentrations indicated for 6 hours or left untreated. Medium containing various concentrations of desferrioxamine.

Cancer Res 2005; 65: (23). December 1, 2005 10856 www.aacrjournals.org

Transferrin receptor levels correlate with sensitivity to DHA and with iron-dependent toxicity in HeLa cells. Figure 2.

Results and Discussion

Artemisinin and derivative compounds exhibit a differential cytotoxicity to human papillomavirus–expressing cell lines. Artemisinin and several of its natural and synthetic derivatives have been shown to exhibit varying antimalarial activities (3, 22, 23). To determine if artemisinin and its derivatives also might differ in their antitumor cell activity, we compared their abilities to inhibit (+)-actin antibody (1:10,000) to ensure equal loading.

The blot was reprobed with anti-transferrin receptor antibody (1:1,000). The blot was examined for transferrin receptor level. Equal numbers of cells were plated and 24 hours later were harvested for Western blot analysis. The protein was transferred to a PVDF membrane and probed with antitransferrin receptor antibody (1:10,000) to ensure equal loading. The blot shows a clear increase in the amount of transferrin receptor in immortalized and tumorigenic cell lines as compared with normal cells and this correlates with their increased sensitivity to DHA treatment. Denaturations for iron in each cell line preparation were established employing the internal standard method and a five-point calibration curve using 0.1, 0.5, 1.0, 2.5, and 5 μg/mL standard solutions prepared by serial dilution from a 1.000-μg Fe/L stock solution (Spex Industries, Edison, NJ). We used the method of internal standard to accurately measure iron by inductively coupled plasma-optical emission spectrometry. Using this method, a known amount of internal standard (0.1 mL of 70 μg/mL gallium standard) is added to both the standards and the samples. Known mixtures of standard and analyte are used to construct a calibration curve and the ratio of varied Fe signal to the constant Ga concentration in the sample is used to calculate the sample concentration. An internal standard is useful to correct for any interference due to sample matrix, particularly with biological samples, and to account for any sample loss. Distilled deionized water from the Millipore Ultrapure Water System was used for the preparation and dilution of all standards and cell cultures. Before the analysis, samples were digested in 1% nitric acid (Ultra-Pure Optima Grade, Sigma Chemical) employing a microwave digestor (CEM Industries, Salt Lake City, UT) at a constant temperature and pressure. The samples and standards were introduced into the inductively coupled plasma-optical emission spectrometry at a flow of 1 mL/min and were analyzed at 1.200-W radio frequency power, 0.8 L/min nebulizer gas flow, 15 L/min plasma gas glow, and 1.2 L/min auxiliary gas flow. Two emission wavelengths were used for the determination of iron by inductively coupled plasma-optical emission spectrometry at 239.562 and 259.940 nm. The gallium internal standard was monitored at an emission wavelength of 294.364 nm. Samples containing the cell lines were prepared in duplicate and each sample was measured in triplicate (accumulation time of 20 seconds per replicate) with a relative SD of <2 relative units.

**In vivo canine papillomavirus assay.** Although under anesthesia, both sides of the oral mucosa of six 10-week-old, female beagle dogs were abraded and infected with canine oral papillomavirus (500 ng based on L1 concentration) as previously described (21). Twenty-four hours later, the infected areas of three dogs were treated with 100 μL of DHA dissolved in DMISO (78 mmol/L). Control dogs were treated with 100 μL of DMISO. The dogs were treated once daily for 1 minute, five times a week, for the duration of the experiment. Every 3rd day, the dogs were anesthetized for a more thorough treatment and photography. Blood was drawn on three separate occasions at 1, 3, and 5 weeks after tumor formation started.

**ELISA analysis of dog serum for L1 antibody production.** Blood was collected by phlebotomy and serum fractions were prepared. Sodium azide (Sigma Chemical, 20% stock) was added to the serum samples (final concentration of 0.02%) to prevent microbial growth. Wells from a 96-well ELISA plate (Dynex Immulon 2 HB) were coated with the canine oral papillomavirus at a dilution of 1:1,000 (0.1 ng per well) in 5% skim milk for 1 hour at 37°C. Wells were rinsed with PBS and serum was added (diluted 1:50 in 5% skim milk) to the plate and incubated for 1 hour at 37°C. Secondary sheep anti-dog immunoglobulin G conjugated to horseradish peroxidase (HRP) was added at a dilution of 1:5,000 for 1 hour at 37°C. HRP was activated with the TMB Microwell Peroxidase substrate and the reaction was terminated with stop solutions (Kirkegaard & Perry Laboratories, Gaithersburg, MD). Samples were then read in an ELISA plate reader at 450 nm. The results shown are representative of three individual experiments with similar results.

Results and Discussion

Artemisinin and derivative compounds exhibit a differential cytotoxicity to human papillomavirus–expressing cell lines. Artemisinin and several of its natural and synthetic derivatives have been shown to exhibit varying antimalarial activities (3, 22, 23). To determine if artemisinin and its derivatives also might differ in their antitumor cell activity, we compared their abilities to inhibit...
Figure 3. DHA-induced apoptosis is caused by iron-dependent formation of ROS. A, HeLa cells were plated in 100-mm tissue culture dishes and treated with 5 \( \mu \text{mol/L} \) 6-carboxy-2,7-dihydrofluorescein-diacetate (fluorescent probe for ROS) and simultaneously treated with 0 \( \mu \text{mol/L} \) (red line), 25 \( \mu \text{mol/L} \) (blue line), or 100 \( \mu \text{mol/L} \) (purple line) DHA for 3 hours (left). Black lines, untreated cells. Cells were collected and analyzed by flow cytometry. A 2-fold and 4.2-fold increase in fluorescence was observed in cells treated with 25 and 100 \( \mu \text{mol/L} \) DHA, respectively, indicating a dose-dependent increase in production of ROS in response to DHA treatment (left). The production of ROS was markedly inhibited by pretreating the cells with desferrioxamine (right), indicating that the formation of ROS in response to DHA treatment is iron dependent. B, after a 3-day treatment with various concentrations of DHA, control cervical cells (HCX) and HeLa cells were collected and stained with FITC-conjugated Annexin V and propidium iodide for 10 minutes before being subjected to flow cytometry. Control cervical cells (HCX) showed only a minor increase (from 2.7% to 4.4%) in the number of Annexin V– and propidium iodide–positive cells following treatment with DHA (50 \( \mu \text{mol/L} \); top). In contrast, the HeLa cervical cancer cells showed an increase in Annexin V and propidium iodide positivity from 0.1% to 64.8%. In addition, there were 7.6% and 9% propidium iodide and Annexin V singly positive cells, respectively. It seems that there is a rapid progression of Annexin V–positive cells to propidium iodide–positive cells (bottom).

The growth of the HeLa cervical cancer cell line (Fig. 1A). HeLa cells were treated for 3 days with the compounds at 5 to 50 \( \mu \text{mol/L} \) concentrations and viability was measured with neutral red staining as described. Artemisinin had little biological effect on these cells although it is known to exhibit strong antimalarial activity in vivo. We presume that the in vivo activity of artemisinin may rely on its rapid conversion in the liver (and other potential sites) into dihydroartemisinin. Consistent with this hypothesis, we found that DHA was highly effective in killing HeLa cells. Artesunate also displayed a cytotoxic activity equivalent to that observed with DHA. Most importantly, DHA and artemisinin had little or no cytotoxic effect on normal cervical epithelial cells (Fig. 1B) even at 50 \( \mu \text{mol/L} \) concentrations. As anticipated from its lack of effect on HeLa cells, artemisinin also had no effect on normal cervical cells.

Because DHA is the predominant metabolite of artemisinin and displayed a highly selective cytotoxic activity for the HeLa cell line, we selected this compound for further study and screened its activity against two additional tumorigenic cervical cancer cell lines, SiHa and Caski, two HPV-immortalized nontumorigenic cervical cell lines expressing E6 and E7 together [preimmortalization (p5) and postimmortalization (p50)], and two cell lines expressing E6 and E7 independently. Again, cervical cells transfected with empty retrovirus were included as a control. Figure 1C shows that DHA is cytotoxic to all HPV-expressing cells regardless of tumorigenicity. Because the HPV-immortalized cells express only the HPV-16 E6 and E7 genes (17, 18), we conclude that the expression of these two viral genes is sufficient for inducing DHA sensitivity. In addition, the sensitivity to DHA seemed to be early after transduction of the E6/E7 genes, suggesting that DHA sensitivity precedes cellular immortalization. In an attempt to determine the potential role of E6 and E7 in the induction of sensitivity to DHA, we examined cells expressing each gene independently. Although both cell lines were slightly less sensitive to DHA when compared with the cell line expressing both genes, we were unable to attribute DHA sensitivity to one gene nor observed an additive effect. Neither gene alone is sufficient to immortalize ectocervical cells whereas each gene is capable of extending the life span of ectocervical cells (data not shown). Thus, whereas all the early passage cells grew at approximately the same rate, the increased growth potential seems to be sufficient to sensitize the cells to DHA. Similar to the results in Fig. 1A, DHA had little effect on the normal cervical epithelial cells.

Our results refine and extend published data showing that DHA is twice more effective than artemisinin at inhibiting the growth of four cancer cell lines, one of which was HeLa (8). The previous study determined the IC\(_{50}\) of DHA and artemisinin to be ~16 and 39 \( \mu \text{mol/L} \), respectively, whereas our data suggest that HeLa cells, although sensitive to DHA (IC\(_{50}\) of ~5 \( \mu \text{mol/L} \), are very resistant.
Importantly, this increase in ROS was abrogated when the cells were pretreated with desferrioxamine (Fig. 3A, right). Together, these data show the essential role for intracellular iron in mediating the cytotoxic effects of DHA and that ROS, in fact, are generated in HeLa cells treated with DHA.

We hypothesized that the cytotoxicity secondary to ROS was due to the induction of apoptosis. This first was suggested by the morphologic changes that occur in DHA-treated cervical cancer cells. Treated cells ceased proliferating, rounded up, and detached.

Dihydroartemisinin cytotoxicity is iron dependent. Because the antimalarial activity of DHA and artesunate is dependent on high intraparasite iron content (3), we examined whether the DHA sensitivity of HPV-expressing cells was related to cellular iron content. First, we found that all of the sensitive cell lines expressed higher levels of the transferrin receptor (1.7- to 2.5-fold) than corresponding normal cells (Fig. 2A). The increased level of transferrin receptor in vitro correlates with in vivo data showing increased transferrin receptors in high-grade cervical lesions and cancers as measured by immunohistochemistry (14–16). Thus, the increase in transferrin receptors is not an artifact of in vitro culturing of the cells. This receptor overexpression also was accompanied by higher levels of total intracellular iron. When the intracellular iron content of HeLa cells and normal ectocervical cells was measured by inductively coupled plasma optical emission spectrometry, we found that HeLa cells contained 50% more iron (1.3 versus 0.88 pg per cell, respectively). Whereas the absolute level of transferrin receptor and total cellular iron in HeLa cells was elevated, it did not seem to correlate strictly with the dramatic increase in DHA sensitivity. This could have several etiologies. For example, although we have measured total cellular iron, we have not been able to quantify the level of ferrous iron, the form that reacts with the DHA endoperoxide bond to generate ROS. It is possible that there is a greater difference in the level of ferrous iron in the normal and HPV-expressing cells. In addition, because HPV-expressing cells are sensitized to apoptosis by the E6 and E7 proteins, it is possible that it only takes slight increases in iron content to amplify DHA cell toxicity.

To provide a more direct evidence for the role of iron in DHA-induced cytotoxicity, we specifically chelated the iron in the cell cultures with desferrioxamine. As shown in Fig. 2B, DHA cytotoxicity was reversed in a dose-dependent manner, indicating an essential role for iron. To circumvent potential toxicity associated with prolonged exposure of cells to desferrioxamine (24), we did these experiments with increased amounts of DHA, allowing the exposure time to be decreased from 3 days to overnight. Under these conditions, there was no detectable effect of desferrioxamine on cell viability and cells were strongly protected against DHA effects.

Dihydroartemisinin induces reactive oxygen species in cervical cancer cells via an iron-dependent mechanism. To determine if the DHA cytotoxicity observed in HeLa cells truly reflected the hypothesized generation of iron-dependent ROS, we measured the induction of ROS in HeLa cells using 6-carboxy-2',7'-dihydrofluorescein-diacetate as shown in Fig. 3A. This cell-permeating, nonfluorescent probe is oxidized by ROS and converted into a fluorescent product, 2',7'-dichlorofluorescein, which can be measured using FACS. Thus, an increase in fluorescence indicates an increase in the level of ROS. HeLa cells show a significant, dose-dependent increase in ROS (Fig. 3A, left). Importantly, this increase in ROS was abrogated when the cells were pretreated with desferrioxamine (Fig. 3A, right). Together, these data show the essential role for intracellular iron in mediating the cytotoxic effects of DHA and that ROS, in fact, are generated in HeLa cells treated with DHA.

Additional evidence that ROS contributed to the cytotoxic effects of DHA was provided by the observation that pretreating the cells with the iron chelator desferrioxamine (Fig. 3B, right). The E7 protein was detected using a monoclonal antibody at 1:500. Both blots were reprobed with anti-β-actin antibody (1:10,000) to ensure equal loading.
from the plate, suggesting an apoptotic process (data not shown). To determine the mode of DHA-induced cell death, we stained normal and cancer cells with fluorescent Annexin V and propidium iodide (which measure early and late events in apoptosis, respectively) and quantified their fluorescence by flow cytometry. Untreated normal cervical cells showed a low background of staining with either Annexin V or propidium iodide (2-3%) and this staining was only marginally increased (2-4%) when treated with increasing concentrations of DHA for 3 days (Fig. 3B, top). In contrast, DHA-treated cervical cancer cells stained with Annexin V and rapidly became propidium iodide positive (Fig. 3B, bottom), indicating irreversible loss of membrane integrity. After 3 days in 50 μmol/L DHA, ~65% of the cervical cancer cells were stained positively with propidium iodide with an additional 9% staining positive for Annexin V.

**Dihydroartemisinin-induced apoptosis proceeds via the mitochondrial pathway and is p53 and viral oncoprotein independent.** To define the apoptotic pathway(s) being activated by DHA, we did Western blot analysis of DHA-treated cells using a panel of caspase antibodies. Figure 4A shows that caspase-9 was activated in response to DHA, indicating the involvement of the mitochondrial apoptotic pathway (reviewed in ref. 25). However, there was no activation of caspase-12 (an indicator of endoplasmic reticulum stress; reviewed in ref. 26) or caspase-8 and caspase-10 (indicative of receptor-mediated pathways; ref. 27 and data not shown). Apparently, the mitochondrial apoptotic pathway is activated preferentially when cells are treated with DHA. The induction of caspase-9 activates downstream effector caspases, which ultimately leads to the cleavage of cytoskeletal and nuclear proteins such as poly(ADP-ribose) polymerase (28). As shown in Fig. 4B, cleaved poly(ADP-ribose) polymerase was detected easily in cells treated with DHA. The activation of caspase-9 and cleavage of poly(ADP-ribose) polymerase occurred in a dose-dependent manner and was significantly inhibited by preincubating the cells with desferrioxamine (Fig. 4A and B), showing the iron dependence of DHA.

One of the key mediators of the mitochondrial apoptotic pathway is the p53 protein (reviewed in ref. 25), and the treatment of cervical cancer cell lines with chemotherapeutic compounds such as cisplatin often induces elevated levels of p53 even in the presence of the HPV E6 protein (11, 29). It was therefore possible that DHA might be inducing apoptosis by increasing cellular p53 levels. However, as shown in Fig. 4C, we found no increase in the amount of p53 in DHA-treated HeLa cells even at the highest dose of DHA. In addition, there was no increase in the level of p53 in the normal ectocervical cells, which may not be surprising due to the lack of toxicity in these cells. The finding that p53 was not induced in HeLa cells on treatment with DHA suggests a p53-independent mechanism for the activation of caspase-9 and the mitochondrial apoptotic pathway.

The lack of p53 increase in DHA-treated cells also suggests that the expression of the viral E6 protein, in HeLa cells, was not inhibited. Normally, E6 mediates the ubiquitin-dependent degradation of p53 and the continued lack of detectable p53 suggests that E6 protein expression continued in the presence of DHA. However, to independently verify that viral oncoproteins were not altered by DHA, we also quantified the expression of the E7 viral protein by Western blotting. As shown in Fig. 4C (bottom), the level of E7 protein was unaltered by DHA exposure. Thus, apoptosis occurs in HeLa cells even with continued expression of the viral oncoproteins and lack of cellular p53 protein.

**In vivo activity of dihydroartemisinin: the canine papillomavirus model.** Thus far, our data show the ability of DHA to selectively kill cervical cancer cell lines and immortalized cervical cells in vitro. To determine whether these in vitro activities were applicable in vivo, we employed the canine oral papillomavirus model. This animal model has been used for evaluating the efficacy of papillomavirus vaccines and has several features which make it an ideal model for mimicking human mucosal papillomavirus infections, both oral and genital (30). One important advantage of this model is that 100% of challenged animals become infected and develop tumors. A second advantage is that tumor formation can be monitored easily and correlated with immunologic responses. Lastly, the easy accessibility of the tumors allows for topical application of potential antiviral or antitumor compounds.

---

**Figure 5.** In vivo testing of DHA as a topical therapeutic agent. A, a schematic representation of the experimental protocol. Dogs were challenged with canine oral papillomavirus on day 1 with treatments starting 24 hours later. Tumors appeared at ~3 weeks and lasted ~4 to 5 weeks. The experiment was stopped 1 week later, ensuring that no additional tumors were formed. B, representative pictures of dogs with and without tumor formation (left and right, respectively).
Ten-week-old beagles were challenged with purified canine oral papillomavirus on the right and left sides of the gum and buccal mucosa as previously described (21). Twenty-four hours later, the dogs were treated with either DHA or vehicle (DMSO). In experimental group 1, three dogs were treated topically with 2.22 mg DHA dissolved in 100 μL DMSO. Treatment typically lasted from 30 seconds to 1 minute each day. In experimental group 2, challenged dogs were treated with DMSO using an identical application protocol. Figure 5A illustrates the time line of viral challenge, drug treatment, tumor appearance, and tumor regression.

Figure 5B is a photograph of virus-infected dogs treated with DMSO (left) or DHA (right) at ~6 weeks post challenge. The tumor shown in the DMSO-treated dog is representative of the size of tumors observed in all tumor-positive dogs and was taken at the pinnacle of tumor growth. The DHA-treated dog is free of tumor. In addition, the oral mucosa treated with DHA shows no evidence of ulceration or inflammation, consistent with the lack of DHA cytotoxicity for normal epithelial cells in vitro.

Topical application of dihydroartemisinin inhibits the formation of tumors but does not seem to prevent canine oral papillomavirus infection or replication in oral mucosa. Figure 6A summarizes the results of tumor formation in the six dogs. All virus-infected dogs treated with DMSO developed tumors at 3 to 4 weeks post challenge. In contrast, DHA treatment abolished tumor formation in two of three infected animals. In the DHA-treated dog that did develop a tumor (dog 5), the tumor regressed 2 weeks earlier than those in DMSO-treated dogs although the tumor mass was of comparable size to those in control animals. Thus, the absence of tumors in two of the three DHA-treated dogs suggests that DHA is effective in the prevention of tumor formation. Interestingly, visual observations of the oral mucosa at ~3 weeks postinfection showed a similar mucosal “roughness” in all of the challenged dogs (including the DHA-treated animals), which is indicative of early papilloma formation. We postulated, therefore, that DHA might be inhibiting tumor formation rather than virus infection. In an effort to determine if the DHA-treated dogs really had a subclinical viral infection, we did ELISA (in triplicate) on serum samples (taken at the end of the trial) to detect and quantify antibody responses to the L1 viral capsid protein (Fig. 6B). Despite the finding that only one DHA-treated dog developed a tumor, we observed that all DHA-treated dogs developed antibody titers against the L1 protein. This suggests that the tumor-free animals indeed had been infected with virus and that the virus had replicated and synthesized significant amounts of L1 protein. Thus, it seems that DHA inhibits tumor formation rather than viral replication. As anticipated, all of the control animals also developed antibodies to L1, which is normally observed during the natural regression of these tumors.

In summary, our results indicate that DHA can effectively induce apoptosis in HPV-expressing cervical cells and inhibit viral-induced tumor formation in animals. Although our study groups were small, preventing us from performing statistical analysis, it should be emphasized that the canine oral papillomavirus model results in a 100% tumor formation rate and in the past 12 years of working with this model, we have not had a challenged dog that failed to develop tumors. Thus, the absence of tumors in 66% of the treated animals is biologically significant. We are continuing these studies to examine both the inhibition of tumor formation as well as the increased rate of tumor regression. Coupled with the observation that DHA can penetrate mucosal surfaces without inducing cellular damage, it seems that DHA may have clinical applications for the topical treatment of cervical dysplasia and possibly of other mucosal or epidermal neoplasias.

**Acknowledgments**

Received 4/7/2005; revised 8/19/2005; accepted 9/15/2005.

**Grant support:** Mary Kay Ash Foundation and NIH National Center for Alternative Medicine grant R21AT002687-01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Vjekoslav Tomaic and members of the Department of Comparative Medicine, Dr. Mary Martin, Jennifer Pass, and Mark Williams, for assistance with the dogs and Michael Liu of Holley Pharmaceuticals for providing us with the dihydroartemisinin and artesunate used in this study.

---

**Figure 6.** DHA significantly inhibits tumor formation while apparently not being able to prevent infection and replication of canine oral papillomavirus. A, tabulation of tumor formation in the dogs. +, presence of a tumor (similar to that shown in Fig. 5B, left). All tumors that formed reached approximately the same size. The tumors in DHA-treated dog regressed slightly faster than the tumors in DMSO-treated dogs. B, ELISA results from dog serum collected during the last week of the study. All dogs were positive for antibodies against L1, indicating an initial infection in all dogs. Dogs 4 and 6 failed to form tumors although they had antibodies against L1, suggesting DHA can inhibit tumor formation without inhibiting the initial infection or replication of the virus.
References
Dihydroartemisinin Is Cytotoxic to Papillomavirus-Expressing Epithelial Cells In vitro and In vivo


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/23/10854

Cited articles
This article cites 29 articles, 4 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/23/10854.full.html#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/65/23/10854.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.